Vimarsana
Biggest News Aggregation in the World

Page 10 - Crossover Management News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Crossover Management. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Crossover Management Today - Breaking & Trending Today

Akouos (NASDAQ:AKUS) Upgraded to "Hold" by Zacks Investment Research - Vimarsana News

Akouos (NASDAQ:AKUS) Upgraded to "Hold" by Zacks Investment Research

Zacks Investment Research upgraded shares of Akouos (NASDAQ:AKUS – Get Rating) from a sell rating to a hold rating in a research note published on Wednesday, Zacks.com reports. According to Zacks, “Akouos, Inc. is a precision genetic medicine company. It develops gene therapies to restore, improve and preserve physiologic hearing. The Company’s product candidate includes […]

Akouos (NASDAQ:AKUS) Upgraded at Zacks Investment Research - Vimarsana News

Akouos (NASDAQ:AKUS) Upgraded at Zacks Investment Research

Akouos (NASDAQ:AKUS – Get Rating) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a report issued on Wednesday, Zacks.com reports. According to Zacks, “Akouos, Inc. is a precision genetic medicine company. It develops gene therapies to restore, improve and preserve physiologic hearing. The Company’s product candidate includes AK-OTOF, […]

IVERIC bio (NASDAQ:ISEE) Upgraded by Zacks Investment Research to "Hold" - Vimarsana News

IVERIC bio (NASDAQ:ISEE) Upgraded by Zacks Investment Research to "Hold"

Zacks Investment Research upgraded shares of IVERIC bio (NASDAQ:ISEE – Get Rating) from a sell rating to a hold rating in a research note published on Monday morning, Zacks.com reports. According to Zacks, “IVERIC bio Inc. is a biotechnology company. It is focused on the discovery and development of novel gene therapy solutions to treat […]

Zacks Investment Research Upgrades Akouos (NASDAQ:AKUS) to "Hold" - Vimarsana News

Zacks Investment Research Upgrades Akouos (NASDAQ:AKUS) to "Hold"

Akouos (NASDAQ:AKUS – Get Rating) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a research report issued on Friday, Zacks.com reports. According to Zacks, “Akouos, Inc. is a precision genetic medicine company. It develops gene therapies to restore, improve and preserve physiologic hearing. The Company’s product candidate includes […]

CymaBay Therapeutics, Inc. (NASDAQ:CBAY) Receives Average Rating of "Buy" from Brokerages - Vimarsana News

CymaBay Therapeutics, Inc. (NASDAQ:CBAY) Receives Average Rating of "Buy" from Brokerages

Shares of CymaBay Therapeutics, Inc. (NASDAQ:CBAY – Get Rating) have earned an average recommendation of “Buy” from the eight research firms that are presently covering the company, Marketbeat reports. Two analysts have rated the stock with a hold rating, five have given a buy rating and one has given a strong buy rating to the […]